Drugstore giant Walgreens Boots Alliance has taken another step in its effort to be viewed as a healthcare provider alternative. Walgreens is collaborating with the behavioral health advocacy group Mental Health America to provide mental health screening to as many as 3 million people through 2017.
Walgreens will pay $500,000 to settle the latest case of a company accused of duping New York consumers over prices.
Walgreens beat Wall Street's earnings expectations for its fiscal second quarter as sales rose nearly 14%, but the nation's largest drugstore chain remained conservative with its outlook for the year.
Slumping stock prices and the quickening pace of change in how providers get paid are testing boards of directors at publicly traded healthcare firms in ways they haven't seen in a generation.
Jumpstart Foundry, a Nashville-based venture fund, is hoping to harness the energy of the young, technology-focused entrepreneurs coming into healthcare and channel it into solving actual business problems of some of the country's largest healthcare companies.
The U.S. Food and Drug Administration approved a new hepatitis C pill developed by Merck & Co. The combination pill Zepatier includes the medications elbasvir and grazoprevir, which attack the liver-destroying virus in two ways.
The nation's largest drugstore chain is telling blood-testing startup Theranos to stop sending samples from its customers to a testing facility that drew regulatory scrutiny over possible patient risks.
Digital health company WebMD Health Corp. is not negotiating a sale despite a media report that tagged UnitedHealth Group and Walgreens Boots Alliance as possible suitors, WebMD said in a statement Thursday.
Walgreens is handing over operations of its 56 in-store health clinics in the Chicago area to Advocate Health Care, the largest hospital network in the state. It's the second time Walgreens Boots Alliance has offloaded some of its clinics to a health system.
Last year ushered in a bevy of new rules and regulations that are already affecting the healthcare industry. But 2016 is expected to be just as eventful.
Valeant Pharmaceuticals CEO J. Michael Pearson is taking a medical leave of absence after he was hospitalized with pneumonia last week. Valeant has recently come under scrutiny for its drug pricing policies, as well as its relationship with the mail-order pharmacy Philidor.
Valeant Pharmaceuticals said Tuesday that the agreement will help to lower the prices of its branded prescription-based dermatological and ophthalmological products by 10%.